Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the …
Over the last 12 months, insiders at Eledon Pharmaceuticals, Inc. have bought $4.57M and sold $0 worth of Eledon Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eledon Pharmaceuticals, Inc. have bought $2.33M and sold $1.29M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BVF PARTNERS L P/IL (10 percent owner) — $86.82M.
The last purchase of 1,927,937 shares for transaction amount of $4.57M was made by BVF PARTNERS L P/IL (10 percent owner) on 2024‑05‑09.
2024-05-09 | 10 percent owner | 1.93M 7.8677% | $2.37 | $4.57M | +16.46% | |||
2023-05-05 | 10 percent owner | 1.98M 11.9399% | $2.31 | $4.57M | -41.42% | |||
2022-11-23 | President | 1,000 0.0072% | $2.60 | $2,597 | -23.11% | |||
2021-12-20 | Chief Executive Officer | 2,000 0.0135% | $4.48 | $8,960 | -30.07% | |||
2021-08-17 | Chief Executive Officer | 4,000 0.0262% | $6.21 | $24,840 | -39.06% | |||
2021-06-11 | CHIEF FINANCIAL OFFICER | 10,000 0.0681% | $8.87 | $88,700 | -46.53% | |||
2021-06-09 | Chief Executive Officer | 3,000 0.0203% | $8.01 | $24,030 | -40.88% | |||
2020-12-02 | Sale | 10 percent owner | 103,200 6.5689% | $21.60 | $2.23M | -63.07% | ||
2020-10-30 | Sale | 10 percent owner | 12,969 0.9094% | $26.64 | $345,559 | -62.38% | ||
2020-10-30 | 10 percent owner | 92,040 6.1626% | $25.44 | $2.34M | -62.38% | |||
2019-05-21 | Sale | Chief Executive Officer | 2,937 0.025% | $1.91 | $5,614 | -66.49% | ||
2019-05-21 | Sale | President | 1,914 0.0163% | $1.91 | $3,658 | -66.49% | ||
2019-05-21 | Sale | See Remarks | 1,058 0.009% | $1.91 | $2,022 | -66.49% | ||
2019-05-20 | Sale | Chief Executive Officer | 11,701 0.1045% | $1.96 | $22,953 | -65.78% | ||
2019-05-20 | Sale | President | 7,623 0.068% | $1.96 | $14,953 | -65.78% | ||
2019-05-20 | Sale | See Remarks | 4,218 0.0377% | $1.96 | $8,274 | -65.78% | ||
2019-05-02 | 646,204 6.2443% | $3.10 | $2M | -76.19% | ||||
2019-05-02 | director | 646,204 6.2443% | $3.10 | $2M | -76.19% | |||
2019-04-30 | Sale | 10 percent owner | 200 0.0017% | $2.70 | $540 | -75.47% | ||
2018-09-12 | President | 16,632 0.1711% | $5.02 | $83,476 | -44.40% |
BVF PARTNERS L P/IL | 10 percent owner | 3361803 5.6275% | $4.04 | 2 | 0 | <0.0001% |
Harrison Seth Loring | 7912079 13.2443% | $4.04 | 1 | 0 | ||
Novartis Bioventures Ltd | 10 percent owner | 4493458 7.5218% | $4.04 | 1 | 9 | |
Apple Tree Partners II - Annex, L.P. | 3568438 5.9734% | $4.04 | 1 | 0 | ||
Chimovits Erez | director | 3183314 5.3287% | $4.04 | 1 | 0 | <0.0001% |
Bvf Inc Il | $8.91M | 11.24 | 4.33M | 0% | +$0 | 0.07 | |
Armistice Capital Llc | $4.73M | 5.97 | 2.3M | +4.93% | +$222,480.00 | 0.02 | |
The Vanguard Group | $2M | 2.52 | 969,121 | +39.36% | +$563,828.11 | <0.0001 | |
Woodline Partners LP | $1.34M | 1.69 | 651,939 | -5.43% | -$77,046.04 | 0.01 | |
Ensign Peak Advisors Inc | $912,582.00 | 1.15 | 443,001 | 0% | +$0 | <0.01 |